Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | UBE2M | P61081 | 6/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7228777 | 0.91 | DPP4 (0.42) | DPP4LTA4HSPHK1 | |
| SCHEMBL1389099 | 0.75 | CYP1A2 (0.41) | LMNATSHRSLC6A2SLC6A3HRH3 | |
| SCHEMBL27811490 | 0.73 | CYP1A2 (0.39) | TSHRSLC6A2SLC6A3HRH3 | |
| SCHEMBL4314801 | 0.71 | POLB (0.43) | SLC6A2 | |
| SCHEMBL27261678 | 0.69 | KMT2A (0.56) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7819314 | 0.68 | TSHR (0.41) | TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9066639 | 0.68 | SLC1A3 (0.46) | TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8043274 | 0.68 | SLC1A3 (0.46) | TSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22875267 | 0.68 | GRIN2B (0.43) | LMNATSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7049996 | 0.67 | CTSL (0.41) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | DPP4 1526/4885LTA4H 2750/4885CSNK1A1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.